Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Oliver Boix"'
Publikováno v:
Statistics in Medicine. 41:5767-5788
An objective of phase I dose-finding trials is to find the maximum tolerated dose; the dose with a particular risk of toxicity. Frequently, this risk is assessed across the first cycle of therapy. However, in oncology, a course of treatment frequentl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfc98a451701491a4d7b3df8a0a8a620
https://doi.org/10.1002/sim.9593
https://doi.org/10.1002/sim.9593
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
Purpose: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF). This first-in-man, phase I dose–escalation study assessed the safety, pharmacokinetic, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c80f812b75f509f0f95d8d4511a9475
https://doi.org/10.1158/1078-0432.c.6520397
https://doi.org/10.1158/1078-0432.c.6520397
Autor:
Victor Moreno, Harvey Wong, Raquel Izumi, Xin Huang, Ahmed M. Hamdy, Joy M. Greer, Melanie M. Frigault, Oliver Boix, Claudia Merz, Isabelle Genvresse, Ray Valencia, Daniel Morillo, Raul Cordoba, Grzegorz Nowakowski, Emerson Lim, Valentina Boni, Jennifer R. Diamond
Supplementary Table from First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::349103a7690abd8eb9a33fa70122d36c
https://doi.org/10.1158/1078-0432.22488152
https://doi.org/10.1158/1078-0432.22488152
Autor:
Martijn P. Lolkema, Ingmar Bruns, Jaap Verweij, Ron H.J. Mathijssen, Simon Langer, Isabelle Genvresse, Prabhu Rajagopalan, Kumar Sankhala, Martin Gutierrez, Joseph P. Eder, Patricia M. LoRusso, Anthony W. Tolcher, Sant P. Chawla, Jennifer R. Diamond, Vivek Subbiah, Oliver Boix, Florence Atrafi
Supplementary Table from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091d189809c695666a51560b3929acf1
https://doi.org/10.1158/1078-0432.22482266.v1
https://doi.org/10.1158/1078-0432.22482266.v1
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
PDF file, 41KB.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::014dc1095ba0e6f04ade76edca1b1c5c
https://doi.org/10.1158/1078-0432.22445144.v1
https://doi.org/10.1158/1078-0432.22445144.v1
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
PDF file, 52KB, Adverse events that led to permanent treatment discontinuation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0012c977ee3864af62502dce8eb60d34
https://doi.org/10.1158/1078-0432.22445141.v1
https://doi.org/10.1158/1078-0432.22445141.v1
Autor:
Martijn P. Lolkema, Ingmar Bruns, Jaap Verweij, Ron H.J. Mathijssen, Simon Langer, Isabelle Genvresse, Prabhu Rajagopalan, Kumar Sankhala, Martin Gutierrez, Joseph P. Eder, Patricia M. LoRusso, Anthony W. Tolcher, Sant P. Chawla, Jennifer R. Diamond, Vivek Subbiah, Oliver Boix, Florence Atrafi
Supplementary Figure from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::045f71938a1d19f332e7f0706c610266
https://doi.org/10.1158/1078-0432.22482275.v1
https://doi.org/10.1158/1078-0432.22482275.v1
Autor:
Victor Moreno, Harvey Wong, Raquel Izumi, Xin Huang, Ahmed M. Hamdy, Joy M. Greer, Melanie M. Frigault, Oliver Boix, Claudia Merz, Isabelle Genvresse, Ray Valencia, Daniel Morillo, Raul Cordoba, Grzegorz Nowakowski, Emerson Lim, Valentina Boni, Jennifer R. Diamond
Supplementary Figure from First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f2a6700edabfc66a9670dca8c598725
https://doi.org/10.1158/1078-0432.22488164.v1
https://doi.org/10.1158/1078-0432.22488164.v1
Autor:
Martijn P. Lolkema, Ingmar Bruns, Jaap Verweij, Ron H.J. Mathijssen, Simon Langer, Isabelle Genvresse, Prabhu Rajagopalan, Kumar Sankhala, Martin Gutierrez, Joseph P. Eder, Patricia M. LoRusso, Anthony W. Tolcher, Sant P. Chawla, Jennifer R. Diamond, Vivek Subbiah, Oliver Boix, Florence Atrafi
Supplementary Data from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8852a80c55cdc858f21c7cab9135476
https://doi.org/10.1158/1078-0432.22482284
https://doi.org/10.1158/1078-0432.22482284
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
PDF file, 71KB, Best responses (maximum reduction in sum of longest diameter of target lesions from baseline) in individual patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b2a7d07a67c24c91c0ee12990bc4bd
https://doi.org/10.1158/1078-0432.22445147
https://doi.org/10.1158/1078-0432.22445147